Study reveals role of the secretome in cancer drug resistance
A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment.
The researchers say factoring in the effects of these cells could improve drug development and provide new insights into the most effective use of existing cancer medications.
The non-cancerous cells form the stroma, which holds the tumour tissues together and represent part of the tumour microenvironment (TME).
They secrete a multitude of different proteins called the secretome into the extracellular space. These proteins can activate or suppress signalling pathways between cells, potentially influencing drug response.
This study is the first to compare the function of the often-studied cancer cell secretome with that of the proteins secreted by stromal cells in the TME.
The research was led by scientists at The Institute of Cancer Research, London, and published in the Journal of Proteome Research.
Cancer-associated fibroblasts
In this study, the researchers focused on cancer-associated fibroblasts (CAFs), one of the most abundant types of stromal cell. CAFs have diverse functions, including the growth of the tumour and drug resistance.
For the purpose of comparison, the team used cell samples from a group of cancers driven by mutations in the KRAS gene.
In the first part of the study, the researchers characterised and compared the proteins secreted by CAFs and KRAS mutant cells. In the second part, they exposed both secretomes to 97 anti-cancer drugs so that they could assess the effects of the proteins secreted by CAFs.
The team used mass spectrometry to identify 5,379 proteins across their samples. They then narrowed these down to the 2,573 proteins believed to be secreted by the cells. They found that the quantity of 123 of these proteins differed significantly between the two secretomes, with 108 being more than twice as abundant in the CAF secretome.
Although some of these 108 proteins are known to be associated with CAF functions, others are relatively understudied. The study authors highlight one, called WNT5B, which they believe warrants further investigation because its similarity to a protein known to promote drug resistance suggests that it might do the same.
Increased resistance to chemotherapy
The drug screen revealed that proteins secreted by CAFs seem to increase resistance to two types of chemotherapy: methotrexate and mercaptopurine (6-MP), but increase sensitivity to urothelial cancers treatment erdafitinib.
The difference in response between the CAF and cancer cell secretomes varied among the nine KRAS mutant cancer cell lines that the team used in the study, highlighting the complexity of treating these cancers.
First author Rachel Lau, who was a PhD student at the ICR at the time of the study and is now a postdoctoral bioinformatician at Queen Mary University of London, said: “This study allowed us to directly compare the secretomes of CAFs and cancer cell lines in a multiplexed manner for the first time. Even though the stroma forms a significant portion of the tumour mass, most drug screens overlook stromal cells and focus on cancer cells alone. Our work has shown that the CAF secretome has the potential to influence the function of cancer cells, highlighting the importance of considering stromal elements as part of cancer drug development.
“On the back of this, we are pleased to be able to share our data with the wider research community. We believe this will accelerate the full characterisation of the CAF secretome, which we hope will help towards overcoming drug resistance in cancer.”
All the raw data from the study has been made publicly available on the PRoteomics IDEntifications Database (PRIDE).
Diana Spencer, Senior Digital Content Editor, DDW
